Clinical trial / 2016
Resveratrol supplementation significantly reduced disease activity and improved oxidative stress markers in patients with active ulcerative colitis.
Fifty-six patients with active mild to moderate ulcerative colitis were randomized to receive either 500 mg/day resveratrol capsules or placebo for 6 weeks. In the resveratrol group, serum SOD increased from 122.28 ± 11.55 to 125.77 ± 10.97, TAC increased from 9.87 ± 1.51 to 11.97 ± 1.61, and serum MDA decreased from 5.62 ± 1.18 to 3.42 ± 1.01 (p < 0.001). In addition, resveratrol supplementation significantly decreased disease activity and improved quality of life compared to baseline (p < 0.001).
- Study type
- Randomized, double-blind, placebo-controlled pilot study
- Who was studied
- 56 patients with active mild to moderate ulcerative colitis
- What was measured
- Disease activity (SCCAIQ), quality of life (IBDQ-9), and oxidative stress markers (serum MDA, SOD, TAC)
THE PAPER
Resveratrol Supplementation and Oxidative/Anti-Oxidative Status in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study.
Samsamikor M, Daryani NE, Asl PR, Hekmatdoost A. Arch Med Res, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.